Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Resistance to second-line drugs in multidrug-resistant tuberculosis.

Udwadia Z.

Lancet. 2013 Feb 23;381(9867):625-6. doi: 10.1016/S0140-6736(13)60342-6. No abstract available.

PMID:
23439096
2.

Resistance to second-line drugs in multidrug-resistant tuberculosis.

Nyang'wa BT, Brigden G, du Cros P, Shanks L.

Lancet. 2013 Feb 23;381(9867):625. doi: 10.1016/S0140-6736(13)60341-4. No abstract available.

PMID:
23439097
3.

Resistance to second-line drugs in multidrug-resistant tuberculosis - Authors' reply.

Dalton T, Cegielski P, Kurbatova E, Ershova J, Caoili JC.

Lancet. 2013 Feb 23;381(9867):626. doi: 10.1016/S0140-6736(13)60343-8. No abstract available.

PMID:
23439099
4.

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators, Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P.

Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30. Erratum in: Lancet. 2012 Oct 20;380(9851):1386.

PMID:
22938757
5.

Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.

Rao NA, Irfan M, Soomro MM, Mehfooz Z.

J Coll Physicians Surg Pak. 2010 Apr;20(4):262-5. doi: 04.2010/JCPSP.262265.

PMID:
20392404
6.

Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Coker R.

Int J Tuberc Lung Dis. 2002 Aug;6(8):649-50. No abstract available.

PMID:
12150473
7.

Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance.

Mitchell SL, Seoudi N, Hutchison DC, Drobniewski FA.

Thorax. 2011 Jul;66(7):630-1. doi: 10.1136/thx.2010.148866. Epub 2010 Sep 29. No abstract available.

PMID:
20880876
8.

Drug resistant tuberculosis.

Singh M, Jayanthi S, Kumar L.

Indian J Pediatr. 2000 Feb;67(2 Suppl):S41-6. Review.

PMID:
11129907
9.

Number of drugs to treat multidrug-resistant tuberculosis.

Seung KJ, Joseph K, Hurtado R, Rich M, Shin S, Furin J, Leandre F, Mukherjee J, Farmer P.

Am J Respir Crit Care Med. 2004 Jun 15;169(12):1336-7; author reply 1337. No abstract available.

PMID:
15187016
10.

[New drugs against multidrug-resistant tuberculosis].

Bouvet É.

Rev Prat. 2014 Sep;64(7):896-7. Review. French. No abstract available.

PMID:
25362760
11.

[Considerations on uses of newly developed anti-tuberculosis drugs for multi-drug resistant tuberculosis].

Mori T, Ogawa K, Shigeto E, Shimao T, Suzuki K, Tsuyuguchi K, Nagai H, Matsumoto T, Mitarai S, Yoshiyama T.

Kekkaku. 2014 Nov;89(11):813-5. Japanese.

PMID:
25730950
13.

Second-line treatment for chronic tuberculosis.

Mohapatra PR, Janmeja AK, Saini V, Das SK, Deb A.

Lancet. 2002 Nov 2;360(9343):1430. No abstract available.

PMID:
12424025
14.

Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuberculosis control.

Hoffner S.

Lancet. 2012 Oct 20;380(9851):1367-9. doi: 10.1016/S0140-6736(12)61069-1. Epub 2012 Aug 30. No abstract available.

PMID:
22938756
15.

Fluoroquinolones in multidrug-resistant tuberculosis.

Mohapatra PR.

Am J Respir Crit Care Med. 2004 Oct 15;170(8):920-1. No abstract available.

PMID:
15475406
16.

Multidrug-resistant tuberculosis and bedaquiline.

Salfinger M, Somoskövi A.

N Engl J Med. 2014 Dec 18;371(25):2435-6. doi: 10.1056/NEJMc1412235#SA1. No abstract available.

PMID:
25517715
17.

Multidrug-resistant tuberculosis and bedaquiline.

Diacon AH, Lounis N, Dannemann B.

N Engl J Med. 2014 Dec 18;371(25):2436. doi: 10.1056/NEJMc1412235. No abstract available.

18.

Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Gupta R, Raviglione MC, Espinal MA.

Int J Tuberc Lung Dis. 2001 Dec;5(12):1078-9. Review. No abstract available.

PMID:
11769764
19.

Indian doctors demand better second line treatment for patients with drug resistant tuberculosis.

Mudur G.

BMJ. 2009 Jan 7;338:b8. doi: 10.1136/bmj.b8. No abstract available.

PMID:
19129305
20.

Linezolid for multidrug-resistant tuberculosis.

Chang KC, Leung CC, Daley CL.

Lancet Infect Dis. 2012 Jul;12(7):502-3. doi: 10.1016/S1473-3099(12)70137-8. No abstract available.

PMID:
22742623

Supplemental Content

Support Center